Aflibercept plus FOLFIRI for 2nd line treatment of metastatic colorectal cancer (mCRC): Long-term safety observation from the global aflibercept safety and quality-of-life (QoL) program (ASQoP)

Basit Öğe Kaydı
dc.authoridCicin, Irfan/0000-0002-7584-3868
dc.authoridChau, Ian/0000-0003-0286-8703
dc.authoridPeeters, Marc/0000-0003-4969-2303;
dc.authorwosidCicin, Irfan/AAQ-5575-2020
dc.authorwosidMaiello, Evaristo/C-5224-2017
dc.authorwosidRiechelmann, Rachel SP/C-3984-2012
dc.authorwosidChau, Ian/ABC-2023-2020
dc.authorwosidPeeters, Marc/C-5525-2013
dc.authorwosidBordonaro, Roberto/AAA-8138-2022
dc.contributor.authorRiechelmann, R.
dc.contributor.authorSrimuninnimit, V.
dc.contributor.authorKavan, P.
dc.contributor.authorDi Bartolomeo, M.
dc.contributor.authorMaiello, E.
dc.contributor.authorCicin, I.
dc.contributor.authorKroening, H.
dc.date.accessioned2024-06-12T11:20:45Z
dc.date.available2024-06-12T11:20:45Z
dc.date.issued2016
dc.departmentTrakya Üniversitesien_US
dc.description41st Annual Congress of the European-Society-for-Medical-Oncology (ESMO) -- OCT 07-11, 2016 -- Copenhagen, DENMARKen_US
dc.description.abstract[Abstract Not Available]en_US
dc.description.sponsorshipEuropean Soc Med Oncolen_US
dc.description.sponsorshipSanofien_US
dc.description.sponsorshipSanofien_US
dc.identifier.doi10.1093/annonc/mdw370.100
dc.identifier.issn0923-7534
dc.identifier.issn1569-8041
dc.identifier.urihttps://doi.org/10.1093/annonc/mdw370.100
dc.identifier.urihttps://hdl.handle.net/20.500.14551/25766
dc.identifier.volume27en_US
dc.identifier.wosWOS:000393912500460en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherOxford Univ Pressen_US
dc.relation.ispartofAnnals Of Oncologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subject[No Keywords]en_US
dc.titleAflibercept plus FOLFIRI for 2nd line treatment of metastatic colorectal cancer (mCRC): Long-term safety observation from the global aflibercept safety and quality-of-life (QoL) program (ASQoP)en_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu